[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388548":3},{"organization":4,"outcomesModule":7,"designInfo":184,"detailedDescription":196,"studyPopulation":71,"armGroups":197,"interventions":210,"overallOfficials":220,"centralContacts":224,"locations":232,"responsibleParty":286,"collaborators":288,"id":292,"slug":293,"hasResults":294,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":294,"sex":300,"minAge":301,"maxAge":302,"enrollmentInfo":303,"targetDuration":71,"studyType":306,"phases":307,"briefSummary":309,"conditions":310,"keywords":71,"overallStatus":235,"whyStopped":71,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":321},{"fullName":5,"class":6},"University Hospital, Montpellier","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":71},[9],{"measure":10,"description":11,"timeFrame":12},"The main outcome measure is the number of exacerbations over the 12 months of follow-up.","An exacerbation is defined according to French recommendations as an \"acute event characterized by worsening of respiratory symptoms (notably cough, sputum and dyspnea) beyond \\[normal\\] daily variation and leading to a modification of treatment: either a simple increase in bronchodilators (in this case, a duration greater than 24 hours is required to define an exacerbation) or the addition of another treatment (antibiotic therapy and \u002F or oral corticosteroid therapy).\"","12 months",[14,17,20,23,27,29,31,33,34,37,38,39,40,41,44,45,46,47,48,51,52,53,54,55,58,59,60,61,62,65,66,67,68,69,72,73,74,75,76,78,79,80,81,82,84,85,86,87,88,90,91,92,93,94,97,98,99,100,101,103,104,105,106,107,109,110,111,112,113,115,116,117,118,119,121,122,123,124,125,127,128,129,130,131,133,134,135,136,137,139,141,144,147,150,153,154,155,156,157,160,161,162,163,164,167,168,169,170,171,174,176,177,178,180,181,183],{"measure":15,"description":16,"timeFrame":12},"The number of mild exacerbations throughout follow-up","A mild exacerbation does not require new additional medicine.",{"measure":18,"description":19,"timeFrame":12},"The number of moderate exacerbations throughout follow-up","Moderate exacerbations require antibiotics or oral corticosteroids (but not hospitalization).",{"measure":21,"description":22,"timeFrame":12},"The number of severe exacerbations throughout follow-up","Severe exacerbations require hospitalization.",{"measure":24,"description":25,"timeFrame":26},"COPD Assessment Test (CAT)","Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.","Baseline (Day 0)",{"measure":24,"description":25,"timeFrame":28},"3 months",{"measure":24,"description":25,"timeFrame":30},"6 months",{"measure":24,"description":25,"timeFrame":32},"9 months",{"measure":24,"description":25,"timeFrame":12},{"measure":35,"description":36,"timeFrame":26},"Sino Nasal Outcome Test 22","The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).",{"measure":35,"description":36,"timeFrame":28},{"measure":35,"description":36,"timeFrame":30},{"measure":35,"description":36,"timeFrame":32},{"measure":35,"description":36,"timeFrame":12},{"measure":42,"description":43,"timeFrame":26},"Cough and sputum assessment questionnaire (CASA-Q)","The four domains of the CASA-Q (cough\u002Fsputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom\u002Fimpact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.",{"measure":42,"description":43,"timeFrame":28},{"measure":42,"description":43,"timeFrame":30},{"measure":42,"description":43,"timeFrame":32},{"measure":42,"description":43,"timeFrame":12},{"measure":49,"description":50,"timeFrame":26},"Visual analogue scale for dyspnea","A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).",{"measure":49,"description":50,"timeFrame":28},{"measure":49,"description":50,"timeFrame":30},{"measure":49,"description":50,"timeFrame":32},{"measure":49,"description":50,"timeFrame":12},{"measure":56,"description":57,"timeFrame":26},"Visual analogue scale for coughing","A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).",{"measure":56,"description":57,"timeFrame":28},{"measure":56,"description":57,"timeFrame":30},{"measure":56,"description":57,"timeFrame":32},{"measure":56,"description":57,"timeFrame":12},{"measure":63,"description":64,"timeFrame":26},"Visual analogue scale for sputum production","A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).",{"measure":63,"description":64,"timeFrame":28},{"measure":63,"description":64,"timeFrame":30},{"measure":63,"description":64,"timeFrame":32},{"measure":63,"description":64,"timeFrame":12},{"measure":70,"description":71,"timeFrame":26},"Rheology: modulus of elasticity of mucus (G ')",null,{"measure":70,"description":71,"timeFrame":28},{"measure":70,"description":71,"timeFrame":30},{"measure":70,"description":71,"timeFrame":32},{"measure":70,"description":71,"timeFrame":12},{"measure":77,"description":71,"timeFrame":26},"Rheology: the viscous module (G '')",{"measure":77,"description":71,"timeFrame":28},{"measure":77,"description":71,"timeFrame":30},{"measure":77,"description":71,"timeFrame":32},{"measure":77,"description":71,"timeFrame":12},{"measure":83,"description":71,"timeFrame":26},"Rheology: The ratio G '' \u002F G '",{"measure":83,"description":71,"timeFrame":28},{"measure":83,"description":71,"timeFrame":30},{"measure":83,"description":71,"timeFrame":32},{"measure":83,"description":71,"timeFrame":12},{"measure":89,"description":71,"timeFrame":26},"Rheology: the critical constraint (tau-C).",{"measure":89,"description":71,"timeFrame":28},{"measure":89,"description":71,"timeFrame":30},{"measure":89,"description":71,"timeFrame":32},{"measure":89,"description":71,"timeFrame":12},{"measure":95,"description":71,"timeFrame":96},"Spirometry: forced expiratory volume in 1 minute (FEV1)","Baseline (day 0)",{"measure":95,"description":71,"timeFrame":28},{"measure":95,"description":71,"timeFrame":30},{"measure":95,"description":71,"timeFrame":32},{"measure":95,"description":71,"timeFrame":12},{"measure":102,"description":71,"timeFrame":96},"Spirometry: forced vital capacity (FVC)",{"measure":102,"description":71,"timeFrame":28},{"measure":102,"description":71,"timeFrame":30},{"measure":102,"description":71,"timeFrame":32},{"measure":102,"description":71,"timeFrame":12},{"measure":108,"description":71,"timeFrame":96},"Spirometry: FEV1\u002FFVC",{"measure":108,"description":71,"timeFrame":28},{"measure":108,"description":71,"timeFrame":30},{"measure":108,"description":71,"timeFrame":32},{"measure":108,"description":71,"timeFrame":12},{"measure":114,"description":71,"timeFrame":96},"Plethysmography for lung volumes: residual volume (RV)",{"measure":114,"description":71,"timeFrame":28},{"measure":114,"description":71,"timeFrame":30},{"measure":114,"description":71,"timeFrame":32},{"measure":114,"description":71,"timeFrame":12},{"measure":120,"description":71,"timeFrame":96},"Plethysmography for lung volumes: functional residual capacity (FRC)",{"measure":120,"description":71,"timeFrame":28},{"measure":120,"description":71,"timeFrame":30},{"measure":120,"description":71,"timeFrame":32},{"measure":120,"description":71,"timeFrame":12},{"measure":126,"description":71,"timeFrame":96},"Plethysmography for lung volumes: total lung capacity (TLC)",{"measure":126,"description":71,"timeFrame":28},{"measure":126,"description":71,"timeFrame":30},{"measure":126,"description":71,"timeFrame":32},{"measure":126,"description":71,"timeFrame":12},{"measure":132,"description":71,"timeFrame":96},"Plethysmography for lung volumes: RV\u002FTLC",{"measure":132,"description":71,"timeFrame":28},{"measure":132,"description":71,"timeFrame":30},{"measure":132,"description":71,"timeFrame":32},{"measure":132,"description":71,"timeFrame":12},{"measure":138,"description":71,"timeFrame":12},"Drug consumption throughout the study.",{"measure":140,"description":71,"timeFrame":12},"The number of adverse events will be recorded throughout the study.",{"measure":142,"description":143,"timeFrame":12},"Episodes of exacerbation throughout the study","For each exacerbation, the beginning and end dates will be recorded.",{"measure":145,"description":146,"timeFrame":12},"Episodes of hospitalization throughout the study","For each hospitalization, the beginning and end dates will be recorded.",{"measure":148,"description":149,"timeFrame":12},"Clinical improvement","Clinical improvement is scored via a point system from 0 to 3 at the end of the study. The points are added-up as follows:\n\n* 1 point: no more than one exacerbation without hospitalization during the 52 weeks of follow-up;\n* 1 point: gain \\> 100mL in pre-bronchodilator FEV1 at the 52nd week compared to the baseline state;\n* 1 point: variation of the CAT score during the 52 weeks of observation \\> 2.",{"measure":151,"description":152,"timeFrame":96},"Medical outcomes study 36-Item Short Form Survey (SF-36)","The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy\u002Ffatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.",{"measure":151,"description":152,"timeFrame":28},{"measure":151,"description":152,"timeFrame":30},{"measure":151,"description":152,"timeFrame":32},{"measure":151,"description":152,"timeFrame":12},{"measure":158,"description":159,"timeFrame":96},"EQ-5D-5L","In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain\u002Fdiscomfort, anxiety\u002Fdepression), each described by five levels of intensity (\"no problems\", \"slight problems\", \"moderate problems\", \"severe problems\" and \"extreme problems or complete inability\"). The respondent must indicate one intensity level for each dimension.",{"measure":158,"description":159,"timeFrame":28},{"measure":158,"description":159,"timeFrame":30},{"measure":158,"description":159,"timeFrame":32},{"measure":158,"description":159,"timeFrame":12},{"measure":165,"description":166,"timeFrame":96},"St-George's Respiratory Questionnaire","Scores range from 0 to 100, with higher scores indicating more limitations.",{"measure":165,"description":166,"timeFrame":28},{"measure":165,"description":166,"timeFrame":30},{"measure":165,"description":166,"timeFrame":32},{"measure":165,"description":166,"timeFrame":12},{"measure":172,"description":173,"timeFrame":96},"Blood cell differential: neutrophil levels","A complete blood cell differential will be taken, including neutrophilia and eosinophilia.",{"measure":175,"description":173,"timeFrame":96},"Blood cell differential: eosinophil levels",{"measure":172,"description":173,"timeFrame":12},{"measure":175,"description":173,"timeFrame":12},{"measure":179,"description":71,"timeFrame":96},"Serum Club cell secretory protein",{"measure":179,"description":71,"timeFrame":12},{"measure":182,"description":71,"timeFrame":96},"Sputum bacteriology",{"measure":182,"description":71,"timeFrame":12},{"allocation":185,"interventionModel":186,"interventionModelDescription":187,"primaryPurpose":188,"observationalModel":71,"timePerspective":71,"maskingInfo":189},"RANDOMIZED","PARALLEL","Randomized controlled trial comparing outcomes in 2 parallel arms (36 vs 36 patients).","TREATMENT",{"masking":190,"maskingDescription":191,"whoMasked":192},"TRIPLE","CASA-Q scoring is performed by the patient and then sealed away from investigator-view. Similarly, mucus rheology results are blinded. The patient does not know what arm he\u002Fshe is in, as so does not know exactly why the prescription was made or not.\n\nSimilarly, investigators\u002Foutcome assessors are blinded to both CASA-Q scores and sputum rheology. The prescription strategy is determined according to an algorithm, and investigators\u002Foutcome assessors do not know what arm the patient is in nor exactly why a prescription was made or not.",[193,194,195],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR","The secondary objectives are to compare between the 2 arms:\n\n* exacerbation number according to their severity (observed throughout the duration of the study);\n* the evolution of the symptoms, the rheology of the sputum, and the pulmonary function (measurements repeated every three months);\n* medication consumption and adverse events (monitored throughout the duration of the study);\n* patient trajectories during follow-up;\n* the overall clinical improvement at the end of the study and the evolution of the quality of life (measurements repeated every 3 months);\n* the change in biomarkers of interest (baseline versus end of study).",[198,204],{"label":199,"type":200,"description":201,"interventionNames":202},"Azithromycin according to symptoms","ACTIVE_COMPARATOR","Patients randomized to this arm will be prescribed azithromycin in function of their symptoms.",[203],"Drug: Azithropycin according to symptoms",{"label":205,"type":206,"description":207,"interventionNames":208},"Azithromycin according to rheology","EXPERIMENTAL","Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology.",[209],"Drug: Azithromycin according to rheology or symptoms",[211,216],{"type":212,"name":213,"description":214,"armGroupLabels":215,"otherNames":71},"DRUG","Azithropycin according to symptoms","Patients randomized to the \"standardized comparator arm\" will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \\\u003C70 to homogenize practices between centers).\n\nCASA-Q will be evaluated every 3 months.\n\n* If the patient has a sputum symptoms score \\\u003C70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \\\u003C70.\n* If the patient has a sputum symptoms score\\> 70, management is not changed.",[199],{"type":212,"name":217,"description":218,"armGroupLabels":219,"otherNames":71},"Azithromycin according to rheology or symptoms","Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \\\u003C70).\n\nThe rheology of mucus will be quantified every 3 months.\n\n* If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \\> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.\n* If the patient has a sputum symptoms score \\\u003C70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \\\u003C70.\n* If the patient has a sputum symptoms score\\> 70, management is not changed.",[205],[221],{"name":222,"affiliation":5,"role":223},"Jérémy Charriot, MD","STUDY_DIRECTOR",[225,229],{"name":222,"role":226,"phone":227,"phoneExt":71,"email":228},"CONTACT","04 67 33 67 33","j-charriot@chu-montpellier.fr",{"name":230,"role":226,"phone":227,"phoneExt":71,"email":231},"Arnaud BOURDIN, MD","a-bourdin@chu-montpellier.fr",[233,249,267],{"facility":234,"status":235,"city":236,"state":71,"zip":71,"country":237,"countryCode":238,"cosmosGeoPoint":239,"geoPoint":244,"contacts":245},"University Hospitals of Bordeaux","RECRUITING","Bordeaux","France","FR",{"type":240,"coordinates":241},"Point",[242,243],-0.58046,44.84124,{"lat":243,"lon":242},[246],{"name":247,"role":248,"phone":71,"phoneExt":71,"email":71},"Maéva Zysman, MD, PhD","PRINCIPAL_INVESTIGATOR",{"facility":250,"status":235,"city":251,"state":71,"zip":252,"country":237,"countryCode":238,"cosmosGeoPoint":253,"geoPoint":257,"contacts":258},"University Hospitals of Montpellier","Montpellier","34925",{"type":240,"coordinates":254},[255,256],3.87635,43.61093,{"lat":256,"lon":255},[259,260,263,265],{"name":222,"role":248,"phone":71,"phoneExt":71,"email":71},{"name":261,"role":262,"phone":71,"phoneExt":71,"email":71},"Arnaud Bourdin, MD, PhD","SUB_INVESTIGATOR",{"name":264,"role":262,"phone":71,"phoneExt":71,"email":71},"Anne-Sophie Gamez, MD",{"name":266,"role":262,"phone":71,"phoneExt":71,"email":71},"Jean Romain, MD",{"facility":268,"status":235,"city":269,"state":71,"zip":71,"country":237,"countryCode":238,"cosmosGeoPoint":270,"geoPoint":274,"contacts":275},"University Hospitals of Toulouse","Toulouse",{"type":240,"coordinates":271},[272,273],1.44367,43.60426,{"lat":273,"lon":272},[276,278,280,282,284],{"name":277,"role":248,"phone":71,"phoneExt":71,"email":71},"Laurent Guilleminault, MD",{"name":279,"role":262,"phone":71,"phoneExt":71,"email":71},"Alain Didier, MD, PhD",{"name":281,"role":262,"phone":71,"phoneExt":71,"email":71},"Danielle Brouquieres, MD",{"name":283,"role":262,"phone":71,"phoneExt":71,"email":71},"Nicolas Guibert, MD",{"name":285,"role":262,"phone":71,"phoneExt":71,"email":71},"Sandrine Pontier Marchandise, MD",{"type":287,"investigatorFullName":71,"investigatorTitle":71,"investigatorAffiliation":71,"oldNameTitle":71,"oldOrganization":71},"SPONSOR",[289],{"name":290,"class":291},"Rheonova","UNKNOWN","100388548","phase-4-chronic-airway-disease-mucus-rheology-and-exacerbations-100388548",false,"NCT04339270","Chronic Airway Disease, Mucus Rheology and Exacerbations","Chronic Airway Disease, Mucus Rheology and Exacerbations: a Randomized Controlled Trial of COPD Patients","COPD-CARhE","Inclusion Criteria:\n\n* Subjets between 40 - 85 years (included)\n* Written and signed informed consent form\n* Subjects must be able to attend all planned visits and comply with all test procedures\n* Beneficiary of or affiliated with the French social security system\n* Man or woman with chronic obstructive pulmonary disease for at least 1 year defined according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and validated by the clinical investigator\n* Optimal treatment according to GOLD class severity C or D recommendations\n* \\>=3 exacerbation (regardless of severity: mild-moderate-severe) or ≥ 1 severe exacerbations (requiring hospitalization) in the past 12 months\n* Spontaneous or induced sputum production\n* Electrocardiogram: corrected distance between Q and T waves (QTC) \\\u003C450 ms in men, QTC \\\u003C470 ms in women\n* Normal audiogram for age or absence of contraindication to azithromycin for long course according to Oto-Rhino-Laryngological specialist opinion\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Patients who are prisoners or under other forms of judicial protection\n* Patients under any form of guardianship\n* Participation in another interventional protocol, (current or during the month preceding inclusion)\n* Received azithromycin in the past 3 months\n* Patient whose primary diagnosis is bronchial dilation based on CT scan documentation\n* Known hypersensitivity to azithromycin, erythromycin, any other macrolide, ketolide or any of the excipients of the azithromycin-based specialty used\n* Concomitant use of medication contraindicated with azithromycin (dihydroergotamine, ergotamine, cisapride, colchicine)\n* Other respiratory diseases or associated lung infections\n* Severe hepatic insufficiency and severe cholestasis (a liver biological test will be carried out if clinical suspicion)\n* Renal impairment with creatinine clearance \\\u003C 40 mL\u002Fmin\n* Patients with hematological malignancies who have undergone allogeneic hematopoietic stem cell transplantation\n* Patients with galactose intolerance, Lapp lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary disease) due to the presence of lactose in the specialty Zithromax.","ALL","40 Years","85 Years",{"count":304,"type":305},72,"ESTIMATED","INTERVENTIONAL",[308],"PHASE4","The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.",[311],"Chronic Obstructive Pulmonary Disease","2026-09-21",{"date":314,"type":315},"2026-09-24","ACTUAL",{"date":317,"type":315},"2023-02-03",{"date":319,"type":305},"2027-02",{"name":5,"class":6},3]